Cargando…
自身抗体预后标志物在肿瘤免疫检查点抑制剂治疗中的临床价值
Serum autoantibody markers have the advantages of easy specimen acquisition, simple detection technology and dynamic real-time monitoring. With the wide application of immune checkpoint inhibitors in the treatment of malignant tumors, autoantibody markers in predicting tumor immune checkpoint inhibi...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346161/ https://www.ncbi.nlm.nih.gov/pubmed/35899453 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.28 |
| _version_ | 1784761586034933760 |
|---|---|
| collection | PubMed |
| description | Serum autoantibody markers have the advantages of easy specimen acquisition, simple detection technology and dynamic real-time monitoring. With the wide application of immune checkpoint inhibitors in the treatment of malignant tumors, autoantibody markers in predicting tumor immune checkpoint inhibitors efficacy and forecasting irAEs (immune related adverse events) show good prediction of potential. This review mainly focused on the progress of autoantibody markers in the prediction of therapeutic effect and the monitoring of irAE in tumor immunotherapy. |
| format | Online Article Text |
| id | pubmed-9346161 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93461612022-08-17 自身抗体预后标志物在肿瘤免疫检查点抑制剂治疗中的临床价值 Zhongguo Fei Ai Za Zhi 肺癌创新药物研发 Serum autoantibody markers have the advantages of easy specimen acquisition, simple detection technology and dynamic real-time monitoring. With the wide application of immune checkpoint inhibitors in the treatment of malignant tumors, autoantibody markers in predicting tumor immune checkpoint inhibitors efficacy and forecasting irAEs (immune related adverse events) show good prediction of potential. This review mainly focused on the progress of autoantibody markers in the prediction of therapeutic effect and the monitoring of irAE in tumor immunotherapy. 中国肺癌杂志编辑部 2022-07-20 /pmc/articles/PMC9346161/ /pubmed/35899453 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.28 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
| spellingShingle | 肺癌创新药物研发 自身抗体预后标志物在肿瘤免疫检查点抑制剂治疗中的临床价值 |
| title | 自身抗体预后标志物在肿瘤免疫检查点抑制剂治疗中的临床价值 |
| title_full | 自身抗体预后标志物在肿瘤免疫检查点抑制剂治疗中的临床价值 |
| title_fullStr | 自身抗体预后标志物在肿瘤免疫检查点抑制剂治疗中的临床价值 |
| title_full_unstemmed | 自身抗体预后标志物在肿瘤免疫检查点抑制剂治疗中的临床价值 |
| title_short | 自身抗体预后标志物在肿瘤免疫检查点抑制剂治疗中的临床价值 |
| title_sort | 自身抗体预后标志物在肿瘤免疫检查点抑制剂治疗中的临床价值 |
| topic | 肺癌创新药物研发 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346161/ https://www.ncbi.nlm.nih.gov/pubmed/35899453 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.28 |
| work_keys_str_mv | AT zìshēnkàngtǐyùhòubiāozhìwùzàizhǒngliúmiǎnyìjiǎnchádiǎnyìzhìjìzhìliáozhōngdelínchuángjiàzhí AT zìshēnkàngtǐyùhòubiāozhìwùzàizhǒngliúmiǎnyìjiǎnchádiǎnyìzhìjìzhìliáozhōngdelínchuángjiàzhí |